34 results
424B5
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Prospectus supplement for primary offering
4:04pm
of any golden parachute arrangements not previously approved; and
an exemption from the auditor attestation requirement in the assessment of our … approval of any golden parachute arrangements not previously approved; and
an exemption from the auditor attestation requirement in the assessment of our
424B5
GLUE
Monte Rosa Therapeutics Inc
15 May 24
Prospectus supplement for primary offering
4:04pm
; and
an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.
We may take advantage … in the assessment of our internal control over financial reporting.
We may take advantage of these exemptions until the fifth anniversary of our initial
424B5
tfe5b38
26 Oct 23
Prospectus supplement for primary offering
4:55pm
8-K
EX-99.3
68xwm7q4ceuud7beojcr
17 Oct 23
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
7:55am
8-K
EX-99.4
cb2fqdbjqgp ts5
17 Oct 23
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
7:55am
PRE 14A
650bm0vvf7ezqfh
12 Apr 23
Preliminary proxy
4:07pm
S-3
hqjvy3m4d
1 Jul 22
Shelf registration
5:01pm
S-3
EX-4.6
j2efdhq9ou4 g8btix
1 Jul 22
Shelf registration
5:01pm
S-3
EX-4.5
k3l54lzl2a4pj6i jt8w
1 Jul 22
Shelf registration
5:01pm
DEF 14A
o6b2fsvt
27 Apr 22
Definitive proxy
4:10pm
10-K
ijgdwwxcsebne o5
29 Mar 22
Annual report
4:15pm
10-K
EX-10.20
m1f602okk7 gn29
29 Mar 22
Annual report
4:15pm